Geron is developing first-in-class biopharmaceuticals for the
treatment of cancer and chronic degenerative diseases, including spinal cord
injury, heart failure and diabetes. The company is advancing an anti-cancer
drug and a cancer vaccine that target the enzyme telomerase through multiple
clinical trials in different cancers.
